Recursion Signs a Worldwide License Agreement with Takeda to Develop TAK-733 for Hereditary Cancer Syndrome
Shots:
- Recursion to get exclusive WW rights to develop and commercialize TAK-733 for the treatment of a hereditary cancer syndrome and related areas of oncology
- Recursion will utilize its automated drug discovery platform to discover the potential of TAK-733 by testing 200+ potential molecules from Takeda’s library against cancers carrying mutations
- TAK-733 is identified as a potential treatment for a hereditary tumor syndrome using Recursion’s approach for creating cellular models of diseases with inactive genes
Click here to read full press release/ article | Ref: Business wire | Image: Recursion
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
